Ascendis Pharma Growth Disorders A/s
Clinical trials sponsored by Ascendis Pharma Growth Disorders A/s, explained in plain language.
-
Weekly shots aim to boost growth in kids with dwarfism
Disease control ENROLLING_BY_INVITATIONThis study continues testing a weekly injection called TransCon CNP in children and teenagers with achondroplasia, a genetic condition that affects bone growth. It's for participants who have already completed an earlier trial with the same medication. The main goals are to check…
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Weekly injections aim to boost growth in kids with dwarfism
Disease control OngoingThis study is testing whether two weekly injections can safely help children with achondroplasia grow taller. It involves 22 children aged 2-11 years who will receive the treatment for 3 years. Researchers want to see if combining these two medications works better than one alone…
Phase: PHASE2 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC